Cross Country Healthcare, Inc. (CCRN) recently received a neutral rating from Michael Piccolo at Wedbush, indicating a cautious outlook for investors. This rating, issued on May 7, 2026, aligns with the current stock price of $13.09 and suggests minimal upside potential, as the target price sits at $13.25. This analysis provides an opportunity for investors to reassess their positions in CCRN amid tumultuous market conditions.
Recent Price Action
In recent trading sessions, CCRN has exhibited moderate activity, with a slight uptick of approximately 0.03% in its share price. The stock currently trades well below its 52-week high of $18.04, reflecting a striking decline of nearly 49.31%. Conversely, the 52-week low stands at $13.09, indicating a challenging market environment. The stock’s trading volume reached around 919,347 shares, surpassing the average volume of 543,808. This elevated trading activity amidst a relatively low beta of 0.356 suggests investors are increasingly responding to news and changes in market sentiment, though the volatility remains manageable.
Historical Performance
Examining CCRN’s returns over the past 30, 90, and 365 days reveals a distressed performance landscape. Over the last month, the stock has rebounded with a 9.38% gain; however, this is juxtaposed against a stark quarterly decline of 30.67% and an alarming annual drop of 51.71%. The volatility metrics underscore this instability, with weekly volatility reported at 4.79% and monthly volatility at 3.95%. The recent average trading volume over the last ten days stands at 1,136,308, indicating a shift in market interest, though this comes amidst a context of overall decline in stock prices.
Earnings Analysis
In the realm of earnings, CCRN’s latest report revealed a disappointing earnings per share (EPS) figure of -$0.06, falling significantly short of the estimated $0.03 per share. This represents a surprising negative variance of 300%, suggesting substantial challenges to the company’s profitability and operational efficiency. In the previous quarter, the company recorded an EPS of $0.03, also marking a miss against the estimate of $0.04, with a surprise factor of -25%. These figures denote a concerning trend and raise questions about the company’s ability to deliver predictable earnings amidst fluctuating market dynamics.
Consensus Ratings
The overall sentiment among analysts reflects a cautious approach. With three total ratings available, two analysts have issued “Buy” ratings, while one recommends holding the stock. Notably, there are no “Sell” ratings currently, suggesting a baseline of interest in the stock from investors looking for potential recovery. The average price target sits at $14.08, with the highest target reaching $15 and the lowest at $13.25. This range denotes a relatively mixed outlook, reinforcing the neutral stance articulated by Wedbush’s recent analysis.
Stock Grading or Fundamental View
CCRN currently holds a Stocks Telegraph (ST) Grade of 44, a score that encapsulates the company’s current financial health and investment prospects. This rating, while not indicative of robust performance, underscores the firm’s struggle in a challenging environment. A score of 44 typically reflects underlying weaknesses in fundamentals, raising investor queries about growth potential and competitive positioning within the healthcare staffing sector.
Conclusion
For investors contemplating positions in Cross Country Healthcare (CCRN), the stock presents a mixed opportunity. The neutral rating reflects a cautious approach amid high market volatility and disappointing earnings performance. This stock may appeal to those with a higher risk tolerance seeking exposure to a potential turnaround, yet caution is warranted due to the evident operational challenges and significant volatility. Investors should stay abreast of further developments and market sentiment as they assess CCRN’s place in their portfolios.